Article · 4 May 2026
ArticlePublished 26 Aug 2024
Efficacy of Modified Electroconvulsive Therapy in Conjunction with Aripiprazole and Lorazepam in Managing Schizophrenia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
To observe the efficacy of modified electroconvulsive therapy in conjunction with aripiprazole and lorazepam in patients with schizophrenia. The study population for our research comprised 100 patients with schizophrenia, who were admitted to our hospital during the period from June 2022 to June 2023. Two groups were formed; each consisting of 50 randomly assigned patients. For the control group, the treatment regimen included aripiprazole together with lorazepam, while the observation group received modified electroconvulsive therapy in addition to the control group’s treatment for 8 w. Assessment of the patient’s psychological symptoms was conducted utilizing the positive and negative syndrome scale, with their cognitive function assessed using the Wechsler adult intelligence scale. Observations and recordings of any adverse reactions that arose during the treatment were made for both groups. Prior to the initiation of treatment, statistical analysis revealed no significant differences (p>0.05) in positive and negative syndrome scale scores and Wechsler adult intelligence scale scores between the control group and the observation group. Subsequent to the treatment, both groups registered noteworthy declines in positive and negative syndrome scale scores compared to their pre-treatment scores, demonstrating statistical significance (p 0.05). The incorporation of modified electroconvulsive therapy in conjunction with aripiprazole and lorazepam showcases notable efficacy in symptom improvement and cognitive function enhancement for individuals with schizophrenia, accompanied by a commendable safety profile.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Indian Journal of Pharmaceutical Sciences.
Article · 21 Apr 2026
In silico molecular docking analysis of bioactive compounds from Kappaphycus alvarezii and Gracilaria debilis against BRCA1 protein
Article · 11 Mar 2026
Trimethoprim and Sulfamethoxazole-Loaded Nanoparticles Coated With Chitosan for Intranasal Delivery to Treat Cerebral Toxoplasmosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Yiyue Dong”
- BylineArticles whose byline prints “Tianlin Zhang”
- BylineArticles whose byline prints “Shijie Zhu”
- BylineArticles whose byline prints “Yang Xu”
- BylineArticles whose byline prints “Shaxin Liu”